# EXHIBIT C

## Effects of Exposure to Packages of Several Homeopathic Products on Consumer Take-Away and Beliefs

Report submitted to Federal Trade Commission

Manoj Hastak, Ph.D.1

August 2012

<sup>&</sup>lt;sup>1</sup> Manoj Hastak is Professor of Marketing in the Kogod School of Business at American University. He served as a consultant to the FTC on this project.

#### Effects of Exposure to Packages of Several Homeopathic Products on Consumer Take-Away and Beliefs

#### Introduction

A research study was designed to investigate consumer take-away (i.e., ad communication) and beliefs/opinions upon exposure to a package of one of three homeopathic drug products. The three products were: (a) Similasan: claimed to relieve cold-related symptoms in children aged 2-12, (b) Oscillococcinum: claimed to relieve flu symptoms, and (c) Arnica: claimed to relieve pain. The study was designed to address the following questions:

#### Communication

- (1) Does the product package communicate to a significant number of people that it is a homeopathic product?
- (2) Does increasing the prominence of the disclosure on the package that the product is homeopathic improve communication to people that it is a homeopathic product?
  Beliefs/Opinions
  - (3) After viewing the packaging of these homeopathic drug products, do a significant number of people believe that a government agency like the Food and Drug Administration has approved the products as being effective in relieving symptoms associated with the common cold/flu/pain?
  - (4) After viewing the packaging of these homeopathic drug products, do a significant number of people believe that the manufacturer has tested the product on people to show that it is effective in relieving symptoms associated with the common cold/flu/pain?
  - (5) Are the beliefs identified in (4) weakened by the inclusion of a disclosure indicating that the product has not been shown to relieve cold/flu/pain symptoms?
  - (6) Are the beliefs identified in (4) weakened by the inclusion of a disclosure indicating that

the ingredients in the product have not been tested for effectiveness?

The data were collected for the FTC by Decision Analyst. Detailed tabulations of responses to all questions are available in the materials submitted by Decision Analyst to the FTC.

#### Method

The study was conducted online via Decision Analyst's online panel. Details of the panel are included in Appendix A. Respondents were invited to complete the screening questionnaire, and were offered an incentive of \$3 if they were eligible for and participated in the study. Depending on their eligibility, respondents were first assigned to one of the three products (Similasan, Oscillococcinum, or Arnica) and then were randomly assigned to one of three or four package versions for that product (three versions each for Similasan and Oscillococcinum, four versions for Amica -- see next section for details). After they had viewed a 3-D image of the product, respondents answered a short questionnaire comprised of four closed-ended questions. Package Versions

A total of ten mock-ups of packages for the three products were created as follows (see Appendix B for copies of fronts and backs of the ten package versions).

#### (1) Similasan:

Three mock-up packages were created for Similasan: original, homeopathy +, and disclosure #1. The original version was identical to the Similasan package available in the market. The homeopathy + version was identical to the original version except that the word "HOMEOPATHIC" at the top of the package front panel was made larger and more prominent. The disclosure #1 version was identical to the original version except that the statement "This product has not been shown to relieve cold symptoms" was introduced in red lettering in a black box at the bottom of the back panel of the package.

#### (2) Oscillococcinum:

Three mock-up packages were created for Oscillococcinum: original, homeopathy +, and disclosure #1. The original version was identical to the Oscillococcinum package available in the market. The homeopathy + version was identical to the original version except that a second, more prominent "homeopathic" disclosure was added just above the brand name on the front panel. The disclosure #1 version was identical to the original version except that the statement "This product has not been shown to relieve flu-like symptoms" (in red lettering) replaced the contact information for the manufacturer at the bottom of the back panel of the package.

#### (3) Arnica 30X

Four mock-up packages were created for Arnica 30X: original, homeopathy +, disclosure #1, and disclosure #2. The original version was identical to the Arnica package available in the market with the exception that mentions of symptoms ostensibly treated by Arnica (in English and Spanish) as well as company contact information were removed from the back panel. The homeopathy + version was identical to the original version except that the word "HOMEOPATHIC" on the package front panel was made larger and more prominent, and the word "Hyland" (company name) was made smaller (to make room for the bigger "homeopathic" disclosure). The disclosure #1 version was identical to the original version except that the statement "Notice: This product has not been shown to relieve pain symptoms" (in red lettering) was added at the bottom of the back panel. The disclosure #2 version was identical to the original version except that the statement "Notice: The ingredients in this product have not been

<sup>&</sup>lt;sup>2</sup> These changes were necessary in order to fit the disclosure on the back panel of the package, even though it meant that the "original" version of the Arnica package used in the study was not identical to the version available in the market

market.

Thus, the wording and color of lettering for disclosure #1 was identical across the three products while the execution varied slightly.

tested for effectiveness" (in red lettering) was added at the bottom of the back panel.

The front, back, side and top/bottom panels for each of the ten package mock-ups were scanned, and the scanned pictures were used by Decision Analyst to create 3-D images for each of the ten packages. In the study, respondents could zoom in and rotate the 3-D images to look at all sides of a package (see below).

#### Screening Procedure

Screening questions were used to ensure that the respondents were in the target market for at least one the three products (see Questions S1 through S4 in the interview protocol provided in Appendix C). To participate in the survey, respondents had to have purchased for themselves or for a family member one of the three product categories of interest (i.e., a product to relieve (a) cold symptoms for children aged 2-12, (b) pain, or (c) flu-like symptoms) within the past 12 months. In addition, respondents were excluded if they were under 18 or if they (or anyone in their household) worked in marketing research, a grocery or drug store, or for a drug or pharmaceutical company.

#### Main Study Procedure

The study questionnaire is included in Appendix C. Respondents were first given a practice task to familiarize them with relevant online tools and to ensure that they were following instructions carefully. They were shown a 3-D image of a bear and asked to zoom into the image and rotate it so that they could see all sides of the image. They were asked to identify the word/phrase written on the back of the bear. Respondents who were unable to do so were eliminated from the study.

Next, respondents were given the following scenario:

T5: Assume that you are in your local drugstore or grocery store to purchase a product for yourself or a member of your family who is not feeling well. One of the products you

see on display catches your eye, so you pick it up to look at it. This product is displayed on the next screen.

Respondents were then shown a 3-D image of one of the 10 versions of the three study products, and were told:

T6: Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the continue button when you are finished.

Next, respondents were asked a series of closed-ended questions pertaining to ad communication and beliefs/opinions. These questions are explained in the results section.

Soft Launch

Decision Analyst launched the survey and then shut it down after approximately 100 individuals had completed it in order to make sure everything was working properly. They identified no problems during this initial phase.

#### Results

After they had seen a 3-D image of one of the ten packages for the three products, respondents were first asked to identify the product (Q1A). Respondents who correctly identified the name of the product they had seen (Similasan, Oscillococcinum, or Arnica 30X) were asked the ensuing questions. Respondents who were unable to do so were eliminated from the study.

Respondents were next asked the following question:

Q1: Did or didn't the package say or imply anything about relief of (symptoms associated with the common cold/aches and pains/symptoms associated with the flu), or don't you know?

Table 1 shows the percentage of respondents who said "yes, it did" to this question for each of the products and package versions:

TABLE 1<sup>4</sup>
(Q1: Did or didn't the package say or imply anything about relief of (symptoms associated with the common cold/aches and pains/symptoms associated with the flu), or don't you know? (% saying "yes, it did"))

	Original (a)	Homeopathy + (b)	Disclosure 1 (c)	Disclosure 2 (d)
Similasan (n=175/175/175)	88.6%	88.0%	90.9%	_
Oscillococcinum (n=176/175/175)	92.6%	88.0%	91.4%	
Arnica 30X (n=175/177/175/176)	97.1%	96.0%	93.1%	93.8%

These results show that a vast majority of respondents took away the appropriate "relief" claim associated with the product they saw. Also, for each of the three products, there was not a significant difference in the percentage of respondents who took away this claim across the three/four package versions.

Respondents who answered "yes" to Q1 were then shown the following:

T7: We are going to show you three statements about (Similasan/Oscillococcinum/Arnica 30X), one at a time. All, some, or none of these statements may be true. Please look at each statement and then indicate if you believe it is true, or you do not believe it is true, or you don't know or are not sure.

They were then shown the following statements, one at a time, in random order:

Q2A1/A2/A3: A government agency like the Food and Drug Administration has approved (Similasan/Oscillococcinum/Arnica 30X) as being effective in relieving (symptoms associated with the common cold/symptoms associated with the flu/aches and pains).

Q2B1/B2/B3: The manufacturer of (Similasan/Oscillococcinum/Arnica 30X) has tested the product on people to show that it is effective in relieving (symptoms associated with the common cold/symptoms associated with the flu/aches and pains).

Q2C1/C2/C3: The American Medical Association has certified that

<sup>&</sup>lt;sup>4</sup> In this table as well as in subsequent tables, a letter in parenthesis within a cell indicates that that cell percentage was significantly different (at p<.05, two-tailed test) from the corresponding cell percentage in the column designated by the letter.

(Similasan/Oscillococcinum/Arnica 30X) is more effective than other remedies in relieving (symptoms associated with the common cold/symptoms associated with the flu/aches and pains).

In the following tables and discussion, these three statements are abbreviated as (1) FDA approved, (2) Manufacturer tested, and (3) AMA certified. Responses to the FDA approved and Manufacturer tested statements are of focal interest in this study. The AMA certified statement was intended as a control statement designed to capture "yea saying."

Table 2 shows, for each of the three products, the percentage of "yes, I believe that statement is true" responses to (1) the FDA approved statement, (2) the AMA certified statement (i.e., control statement), and (3) the FDA approved statement after the responses to the AMA certified statement have been netted out to control for "yea" saying:

TABLE 2
Responses to FDA approved statement, AMA Certified statement, and net responses
(% saying "yes, I believe that statement is true")

	Original (a)	Homeopathy + (b)	Disclosure 1 (c)	Disclosure 2 (d)
Similasan (n=175/175/175) - FDA Approved Statement	56.0% (b, c)	38.9% (a)	44.6% (a)	
- AMA Certified Statement	27.4%	28.0%	25.7%	
Net	28.6% (b, c)	10.9% (a, c)	18.9% (a, b)	
Oscillococcinum (n=176/175/175) FDA Approved Statement	42.6% (c)	33.1%	24.0% (a)	
- AMA Certified Statement	22.7%	18.3%	16.0%	
- Net	19.9% (c)	14.8% (c)	8.0% (a, b)	
Arnica (n=175/177/175/176) — FDA Approved Statement	32.6% (d)	32.2% (d)	23.4%	19.9% (a, b)
- AMA Certified Statement	22.3% (d)	15.8%	16.0%	12.5% (a)
Net	10.3%	16.4% (c, d)	7.4% (b)	7.4% (b)

These results can be summarized as follows:

(1) Between one-third and three-fifths of respondents exposed to the original product packaging indicated that they believed the FDA statement was true, i.e., that a government agency like the Food and Drug Administration had approved the product (Similasan, Oscillococcinum, or Arnica 30X) as being effective. (Range of responses across the three products: 32.6% to 56%).

- (2) For each product, a somewhat lower percentage of respondents exposed to the Homeopathy + product packaging indicated that they believed the FDA statement was true. (Range of responses across the three products: 32.2% to 38.9%). However, the difference was significant only for Similasan (56.0% versus 38.9%, p<.05 two-tailed).</p>
- (3) Respondents showed less agreement with the FDA statement when exposed to the product packaging with disclosure #1 in comparison to the original packaging for all three products (two of three differences significant at p<.05).</p>
- (4) Respondents showed less agreement with the FDA statement when exposed to the product packaging with disclosure #2 (tested for Arnica 30X only) in comparison to exposure to the original packaging (difference significant at p<.05).</p>

To control for "yea" saying, affirmative responses to the FDA statement were adjusted by subtracting affirmative responses to the AMA statement for each of the temproduct/packaging versions. These adjusted responses indicate that:

- (5) After controlling for "yea" saying, between one-tenth and three-tenths of respondents exposed to the original product packaging indicated that they believed the FDA statement was true. (Range of responses across the three products: 10.3% to 28.6%).
- (6) For two of the three products, a somewhat lower percentage of respondents exposed to the Homeopathy + product packaging indicated that they believed the FDA statement was true. (Range of responses across the three products: 10.9% to 16.4%). However, the difference was significant only for Similasan (28.6% versus 10.9%, p<.05 two-tailed).</p>
- (7) Respondents showed less agreement with the FDA statement when exposed to the product packaging with disclosure #1 in comparison to the original packaging for all three products (two of three differences significant at p<.05).</p>

(8) There was not a statistically significant difference in the level of agreement with the FDA statement when exposed to the product packaging with disclosure #2 in comparison to exposure to the original packaging (tested for Arnica 30X only).

Table 3 shows, for each of the three products, the percentage of "yes, I believe that statement is true" responses to (1) the Manufacturer tested statement, (2) the AMA certified statement (i.e., control statement), and (3) the Manufacturer tested statement after the responses to the AMA certified statement have been netted out to control for "yea" saying:

TABLE 3
Responses to Manufacturer tested statement, AMA Certified statement, and net responses
(% saying "yes, I believe that statement is true")

	Original (a)	Homeopathy + (b)	Disclosure 1 (c)	Disclosure 2 (d)
Similasau (n=175/175/175) — Manufacturer Tested Statement	57.7%	52.6%	52.0%	
- AMA Certified Statement	27.4%	28.0%	25.7%	
Net	30.3%	24.6%	26.3%	
Oscillococcinum (n=176/175/175) - Manufacturer Tested Statement	56.3% (c)	54.9% (c)	38.9% (a, b)	
- AMA Certified Statement	22.7%	18.3%	16.0%	
Net	33.6% (c)	36.5% (c)	22.9% (a, b)	
Aruica (n=175/177/175/176) Manufacturer Tested Statement	45.1%	49.2% (d)	38.9%	38.1 (b)
- AMA Certified Statement	22.3% (d)	15.8%	16.0%	12.5% (a)
Net	22.8% (b)	33.4% (a, c)	22.9% (b)	25.6%

These results can be summarized as follows:

- (1) Between two-fifths and three-fifths of respondents exposed to the original product packaging indicated that they believed the Manufacturer tested statement was true, i.e., that the manufacturer had tested the product (Similasan/Oscillococcinum/Arnica 30X) on people to show that it is effective. (Range of responses across the three products: 45.1% to 57.7%).
- (2) For each product, approximately the same percentage of respondents exposed to the Homeopathy + product packaging indicated that they believed the Manufacturer tested statement was true. (Range of responses across the three products: 49.2% to 54.9%).
- (3) Respondents showed a lower level of agreement with the Manufacturer tested statement when exposed to the product packaging with disclosure #1 in comparison to the original packaging for all three products, but only one difference (for Oscillococcinum) was significant at p<.05.</p>
- (4) There was not a statistically significant difference in the level of agreement with the Manufacturer tested statement when exposed to the product packaging with disclosure #2 in comparison to exposure to the original packaging (tested for Arnica 30X only).

To control for "yea" saying, affirmative responses to the Manufacturer tested statement were adjusted by subtracting affirmative responses to the AMA statement for each of the ten product/packaging versions. These adjusted responses indicate that:

(5) After controlling for "yea" saying, between two-tenths and one-third of respondents exposed to the original product packaging indicated that they believed the Manufacturer tested statement was true. (Range of responses across the three products: 22.8% to 33.6%).

- (6) Approximately the same percentage of respondents exposed to the Homeopathy + product packaging indicated that they believed the Manufacturer tested statement was true. (Range of responses across the three products: 24.6% to 36.5%).
- (7) Respondents showed a lower level of agreement with the Manufacturer tested statement when exposed to the product packaging with disclosure #1 in comparison to the original packaging for two of three products, with one difference (for Oscillococcinum) significant at p<.05.</p>
- (8) There was not a statistically significant difference in the level of agreement with the Manufacturer tested statement when exposed to the product packaging with disclosure #2 (tested for Arnica 30X only) in comparison to exposure to the original packaging. Finally, respondents were asked the following:

Q3: Did or didn't the (Similasan/Oscillococcinum/Arnica 30X) package say that (Similasan/Oscillococcinum/Arnica 30X) is a homeopathic product, or don't you know?

Table 4 shows the percentage of respondents who said "yes, it did" to this question for each of the products and package versions:

TABLE 4

(Q3: Did or didn't the (Similasan/Oscillococcinum/Arnica 30X) package say that

(Similasan/Oscillococcinum/Arnica 30X) is a homeopathic product, or don't you know?

(% saying "yes, it did"))

	Original (a)	Homeopathy + (b)	Disclosure 1 (c)	Disclosure 2 (d)
Similasan	51.4%	71.4%	52.6%	_
(n=175/175/175)	(b)	(a, c)	(b)	
Oscillococcinum (n=176/175/175)	51.1% (b)	64.6% (a)	58.9%	~=
Arnica 30X	60.9%	79.7%	58.3%	58.0%
(n=175/177/175/176)	(b)	(a, c, d)	(b)	(b)

These results may be summarized as follows:

- (1) Between half and six-tenths of respondents exposed to the original product packaging indicated that the package said that Similasan/Oscillococcinum/Amica 30X is a homeopathic product. (Range of responses across the three products: 51.1% to 60.9%).
- (2) For each product, a significantly higher percentage of respondents exposed to the Homeopathy + product packaging indicated that the package said that Similasan/Oscillococcinum/Arnica 30X is a homeopathic product. (Range of responses across the three products: 64.6%% to 79.7%).
- (3) For each product, there were no appreciable differences between respondents exposed to the original packaging and those exposed to packaging with disclosure #1 (for all three products) or disclosure #2 (for Arnica 30X only) on this measure.

#### Conclusion

The study results support the following conclusions in relation to the research questions that were presented earlier:

- (1) Slightly more than half of all respondents exposed to the original product packaging correctly indicated that the packaging said that it is a homeopathic product. The range of correct responses across the three products was 51.1% to 60.9%
- (2) For all three products, exposure to packaging with the enhanced homeopathic disclosure (homeopathy +) significantly increased the number of respondents who indicated that the packaging said that it is a homeopathic product. Across the three products, the increase was in the range of 10% to 20%.
- (3) After controlling for "yea" saying, between one-tenth and three-tenths of respondents

<sup>&</sup>lt;sup>5</sup> The study did not include a control question for Q3; hence these percentages may be somewhat inflated due to "yea saying."

- exposed to the original product packaging for the three products indicated that they believed that a government agency like the Food and Drug Administration had approved the products as being effective. (Range of responses across the three products: 10.3% to 28.6%).
- (4) After controlling for "yea" saying, between two-tenths and three-tenths of respondents exposed to the original product packaging for the three products indicated that they believed the manufacturers had tested the products on people to show their effectiveness. (Range of responses across the three products: 22.8% to 33.6%).
- (5) After controlling for "yea" saying, respondents showed significantly less agreement with the Manufacturer tested statement when exposed to the product packaging with disclosure #1 ("This product has not been shown to relieve cold/flu/pain symptoms") in comparison to the original packaging for one of three products (Oscillococcinum). Thus, the beliefs listed under (4) were significantly weakened by the inclusion of this disclosure for one product only.
- (6) After controlling for "yea" saying, there was not a statistically significant difference in the level of agreement with the Manufacturer tested statement when exposed to the product packaging with disclosure #2 ("The ingredients in this product have not been tested for effectiveness") in comparison to exposure to the original packaging (tested for Arnica 30X only).<sup>6</sup>

<sup>&</sup>lt;sup>6</sup> The apparently limited effect of the two disclosures used in this study on beliefs could be due to a variety of factors, including lack of attention to, comprehension of, or reliance on the disclosure.

## APPENDIX A DECISION ANALYST ONLINE PANEL

#### American Consumer Opinion® Online (Panel Information)

American Consumer Opinion® Online is a proprietary, double opt-in panel of households that have agreed to participate in Internet surveys exclusively for Decision Analyst. The panel currently includes over eight million men, women, and children throughout the United States, Canada, Europe, Latin America, and Asla. Decision Analyst pays the highest incentives of any online panel to help ensure that it maintains a diverse, representative database of consumers, and to motivate its panelists to take the time necessary to provide the most accurate answers possible.

New panel members are continuously recruited by a combination of online and offline methods. The recruiting is designed to make the panel representative of the general adult population within each country. The major methods of recruiting include the following:

- Advertising on hundreds of websites
- Opt-in email lists
- Search engines
- Email newsletters and discussion lists
- Publicity and press releases
- Print advertising

The recruiting methods are designed to reach a broad cross-section of people, using a wide variety of sources, appeals, and websites. The Panel Administrator actively monitors the composition of the panel and adjusts recruiting methods and targets as needed to keep the panel balanced by major demographic variables. Panel recruiting is a constant, ongoing activity.

The panel is continuously cleaned and monitored to ensure the highest levels of accuracy and data integrity. Respondents who attempt to cheat are removed from the panel and blocked from rejoining the panel. Respondents who don't make a good faith effort to accurately answer openend questions are deleted from the panel. Respondents who give the same answer repeatedly (among a list of attributes or statements) are deleted from the panel.

To achieve fully representative samples, Decision Analyst has developed its own advanced software (Icion®) to draw stratified quota samples from the online panel that match the distribution of U.S. households by geography and demography. Samples can be pulled for a whole country, for individual states/provinces or sets of states/provinces, or for large metropolitan areas within states/provinces.

# APPENDIX B STUDY PRODUCT PACKAGES

## Homeopathic Product Packaging Study Package Mock-ups

10/17/11

#### Similasan Front

Original

Homeopathy



Cough Expectorant Syrup

Jarabe Expectorante

Multi-Symptom Cough - Loosens Mucus - Fever Chest & Head Congestion Dye Free

100% Natural Active Ingredients




HOMEOPATHIC

Cough Expectorant Syrup

Jarabe Expectorante

Multi-Symptom Cough - Loosens Mucus - Fever Chest & Head Congestion Dye Free

100% Natural Active Ingredients



#### Similasan Back

#### Original

Efficacy

Active !	Fasts	
hementa	. स्तार्थिक प्रियोध्या । स्तार्थिक स्टब्स्टर्स	Purpos  12X
Kali bother	12X	modil form soom
Senega v To	d atis BX	nany nose, hadi tangesti: espectorant, dry/hacking coug
Uses: Tenporally as coople	refleva symptom aver, chest and bear	associated refit the automore cold, such I congration
Cors ta Core ta sorson Keep this Do not us In case of Dontrol D Do not on Direction	physician il sympto and all medicalicos e il pos-pricali acc. eschi overdos e o branchistaly, and pocurrended ISS:	e, get medical help or contact a Poisson dosage. 4 hours) or as directed by
	DOSE	5 11 (1 50)
ASE		
	2.5 ml (% tap)	
ASE		ZSG Miss)

This product has not been shown to relieve cold symptoms.

#### Oscillococcinum Front

Original

### Flu-like Symptoms

00.0220-9260-33

Feeling Run-Down · Headache · Body Aches · Chills · Fever



No Side Effects o No Drug Interactions o Non-Drowsy

6 doses - 0 04 oz each HOMEOPATHIC MEDICINE BOIRON®

Chuck-Dissolving Polists

Homeopathy

## Flu-like Symptoms

NDC 0220-9280-1

Feeling Run-Down · Headache · Body Aches · Chills · Fever



No Side Effects o No Drug Interactions o Non-Drowsy

6 doses - 0 04 oz cach HDMEOPATHIC MEDICINE BOIRON®



#### Oscillococcinum Back

### Original

Drug Facts	Directions			
Active ingredient Purpose	-s- 1 to 50- 0			
Arms barterin hepath et To reduce the duration coyds extraction 200CK HPUS and severity of fur-tile yrigators.	Adults and children 2 years of age and older	Descrive online contents of one tube or the mouth every 6 hours up to 3 times a day		
The letters HPUS indicate that this rignificant is office by included in the Horseopathic Pharmacopoeta of the United States.	Children younger than 2 years of age	Ask a doctor		
Uses Temporarly referres fu-Siz symptoms such as nun-down for ling, haddedter body activity ordis and fever	Other informati	'an		
Warnings De ool use if glassi carton and flaps are open or if the tray sed is broken.	at store at 68-77*F (20-25*C) In contains 1g of sugar per dose In Bactive ingredients lactore, sucre.			
Anil a doctor before use in children young in than 2 years of soa. Shop use and bait, a doctor if symptoms perses for more than 3 days or wanten. If pregnant or broast-fooding, ask n heath professional before use. Kimp out of miniph of children.				
Que stians, Commento? www.botrousa.com or www.co.com into their num.com 1-500-6000-1 (n.m.562-74))	6 Campus B	m Jion Center Souloverd Quero, PA 19073-3267		

### Efficacy

Drug Facts	Directions		
Active ingredient Purpose	*	<b>6</b> 944	
Anas barberice hepaths at To reduce the duration conduce extraction 2000X HPUS and severity of Rulling one.	Adults and children 2 years of age and older	Dissolver entire contents of one table in the mouth every 6 hours, up to 3 times a day	
The letters HPUS indicate that this ingredient is officially included in the Homoopathic Pharm acoposés of the United States.	Châdren younger then 2 years of age	Ask a doctor	
USBS Temposetly n exist RH-lessymptoms such as run-down in sign headachs, body school, chilosend lever.	Other information store at 68-77°F (20-25°C) tacontains 1g of sugar per dose Inscrive ingredients lactose, sucrose		
Warnings Do not use if gland carton end flaps om open or if the large and is broken.			
Asik a doctor bothre use in children younger than 2 years of age Stop um sund asik a doctor of symptores persent for moru han 3 days or woman.			
f pregnant or breast-feeding, ask a hear's professional sefere use. Keep out of reach of children.			

#### Arnica Front

Original

Homeopathy





#### New Original







#### Arnica 30x

**Drug Facts** Purposes
put & nucle sourcement
extra & policy
extra & policy
extra & policy
house extra
box extra
beare & trigue Acth L Ted res bride stene 300 HPUS. USSES in Temporary ; was the symptoms of areacle pure, surenets, britishing and See lang time to injuries and commentar. See of our six regimes and overcentor.

37 days 34 sets may day, ask a doods before use it program or number is toby.
Caroll a policitin it syngamin passis for more it say? days of second.
Ecop this and it ill medications and of the second children. Do not use if sorper band is before or greater and other or control of second or second or control of second or second or control of sections or present or second or sections or present or second or sections or second or sections or second or sections or second or sections or second or second or sections or section BALLET - 1859 Ark its and officien 12 years and over Descript 1-2 tables under trigge 4 area per they or as meetins Daltim 6-12 years 1/2 seek doze 12 bables may be storn in an ark put and distriction activity or story.

Re cells Impress 5 Lection A

#### Efficacy Disclosure 1



Drug Facts





### Arnica 30x

## Activo Ingre. nts Amica miana 300 HPUS. Purposes Puliposes de moressein, uties à petra, brieng stress hitermation back athe, taura & latique Uses a Temporary referres the comptons of muscle pain, soraress, brilling and swelling due to injuries and overcention. Manufage As \* " any disp, ask a dodor belon use it preport or rusing a baby. Coreal a physician it symptoms panda for he. " fain it days or scose." Keep it is and at medications out of he ment of citation. Do not use it unper band is broken or installing. In case of accidental overlose, coread a posicio cortici enter fransistatis, in case of employing higherod in a becomissioned 24 from a day, if days a week at \$00,624,9859.

Directions Advas and châten 12 years and over Discrice 1-2 black under togal 4 firms per day or as neoted Discrice 5-12 years 1/2 stat daze 1-2 black or y be been indiscription of recovers advalged or runs. In active in representation to Locate HF

Notice The ingredients in this product have not been tested for effectiveness.

#### Efficacy Disclosure 2







#### Arnica 30x

Drug Facts

Activo Ingreso Its Anka Makana 30X HPUS...

Primposes junt & miscle sommercipals extent interpretations social interpretation pack ache teams & tolour

USC of imposely referes the symptoms of muscle part, so mest, but ing and swelling due to injuries and overcomition

What mings 4 a. w. I say thu, ask a codor between 5 in proportion running a beby Done A a physician is symptomic process for more in a 7 days or some.

Seep 1% and as imedications out of the mean of philim. On not use it immyor bend in troken or it. and in medications out of the mean of philim. On not use it immyor bend in troken or it. and in in common the philims of the content of a potent contract in markets, in case of employing it pleasure may be contacted 24 truns a day 7 days a mest bit 500-524-5659.

Directions to Los and dritten 12 years and over, Disable 1-2 totals under largue 4 times per day or as received. Disable 1-12 years 1/2 and 1 drice, 1-2 latiets may be taken in a discussion of strumous schely or injus.

Inactive Imprese mits Lectors NF

Notice. This product has not been shown to relieve pain symptoms.

APPENDIX C
INTERVIEW PROTOCOL

Decision Analyst 817.640.6166

Project Director: Carì Peek

Project #:

20110394

Date:

12/5/2011 2:04 PM

#### **OTC Medicine Package Test**

STUDY INFORMATION:

Capture All Screening Data: Yes

Landing Page: ACOP Disable Back Button: Yes Image Encryption: No

IMPERIUM

#### SA" PLE SPECIFICATIONS

Sample Source: ACOP

Incentive: \$3

Description of Sample: US 50+ DC, Males and Females ages 18+. Exclude marketing, marketing research

and advertising.

#### SAMPLING QUOTAS.

Each respondent will view and rate one package. Package images will be interactive 3D

USE LEAST FILL TO ASSIGN TO ONE CELL/IMAGE WITHIN CELL

Quota 1: CELL 1 -SIMILASAN (COLD SYMPTOMS FOR CHILDREN, S1\_1 = 1) n=525

Quota 2: 1a SIMILASAN IMAGE 1 (n=175)

Quota 3: 1b SIMILASAN IMAGE 2 (n=175)

Quota 4: 1c SIMILASAN IMAGE 3 (n=175)

Quota 5: CELL 2 - ARNICA 30X (RELIEVES PAIN, S1\_2 = 1) n=700

Quota 6: 2a ARNICA IMAGE 1 (n=175)

Quota 7: 2b ARNICA IMAGE 2 (n=175)

Quota 8: 2c ARNICA IMAGE 3 (n=175)

Quota 9: 2d ARNICA IMAGE 4 (n=175)

Quota 10: CELL 3 - OSCILLOCOCCINUM (FLU SYMPTOMS, S1\_3 = 1) n=525

Quota 11: 3a OSC IMAGE 1 (n=175)

Quota 12: 3b OSC IMAGE 2 (n=175)

Quota 13: 3c OSC IMAGE 3 (n=175)

DNQ1 - NONE OF S1\_1, S1\_2, OR S1\_3 = CODE 1 (Haven't purchased medicine past 12 months)

DNQ2 - S2 = CODES 1-4 (SECURITY)

DNQ3 - S3 = CODE 1 (UNDER 18)

DNQ4 - S5 IS NOT CODE 3 (DID NOT SEE TEDDY BEAR IMAGE) DNQ5 - S6 IS NOT CODE 3 (DID NOT SEE WRITING ON BACK OF TEDDY BEAR)

DNQ998 - S7 NOT CODE 3 (CHEATER)

DNQ6 - Q1A INCORRECT PACKAGE SELECTED

#### QUESTIONNAIRE MAP

L1 TOP J Tye, Se LOGIC DISTPUT INS

· iblas c

Please enter your first name and email address in the boxes below.

(PAGE BREAK)

Dear [Insert Respondent (first\_name)]:

Thanks for agreeing to complete this brief screening questionnaire.

As soon as you respond, your name will be entered into a drawing for \$10,000 in monthly cash awards for participating in this screener. If your name is drawn, your account will be credited the following month. For example, if your name were to be drawn in May, your account would be credited during the first week of June.

Your individual answers will be anonymous and strictly confidential, of course. Once you have answered all of the questions on a page, please click on the "Continue" button.

T18 TRYPE TO THE DE PLE ALLAS INDENDITO

(FORM INPUT)(FORM INPUT) (FORM INPUT) (TABLE: not parsed)(JAVASCRIPT CODE)

(PAGE BREAK)


ST TYPE Single RAS CONSTRUCTOR SIDE ALAS ON CONSTRUCTOR SET A SET

Which of the following products, if any, have you purchased for yourself or for a member of your family in the last 12 months?

(Choose One Answer On Each Row Below)

		Yes	No	Not Sure	
S1_1	A product to relieve cold symptoms for a child aged 2-12	1	2	3	
S1_2	A product to relieve pain	1	2	3	
S1_3	A product to relieve flu symptoms	1	2	3	
S1_4	A product to relieve heartburn	1	2	3	1

(PAGE BREAK)



Do you, or does anyone in your household work...? (Choose All Correct Answers)

- 1 In marketing research
- 2 In advertising or public relations
- For a gracery store or drugstore

Decision Analyst

- 4 For a drug or pharmaceutical company
- 5 None of these

(PAGE BREAK)

S3 TYPE: Single Response ALIAS: Age (18 to 75)
LOGIC INSTRUCTIONS: MUST BE CODES 2-4, @THERWISE DN@3

Are you...? (Choose One Answer)

- 1 Under 18
- 2 18 to 34
- 3 35 to 54
- 4 55 or over

S4 TYPE: Single Response ALIAS: Gender LOGIC INSTRUCTIONS:

Are you? (Choose One Answer)

- 1 Male
- 2 Female

(PAGE BREAK)

T17 NVEE ATV TEXTED IN SEAT TO THE PROPERTY OF THE PROPERTY OF

We would like for you to view a 3D image. Instructions are shown at the end of this paragraph to tell you how to rotate and zoom in on the image. Please make sure to rotate and zoom into the image to see all sides of it. After you finish viewing the image, click on the "Continue" button to continue.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

(PAGE BREAK)

What 3D image, if any, did you see? (Choose One Answer)

- 1 Horse
- 2 Bicycle
- 3 Teddy bear
- 4 Dog
- 5 Did not see anything
- 6 Received an error message

S6 TYPE: Single Response ALIAS: Computer System Check - 3D Image (3 of 3)

LOGIC INSTRUCTIONS: RANDOMIZE ANSWERS, DNR CODES 5 & 6

MUST BE CODE 3-HELLO, OTHERWISE DNC, 5

What was written on the back of the image? (Choose One Answer)

- 1 Happy Birthday
- 2 Goodbye
- 3 Hello
- 4 | Love You
- 5 Did not say anything
- 6 Received an error message

(PAGE BREAK)

ST THE SITE BE THE STATE TO WAS AND MITTER AND WEEK VI. STAF CODE 3 VELLOW THE FOWSE POWDER AND WEEK VI. STAF CODE 3 VELLOW THE FOWSE

For quality-control purposes, please select "Yellow" from the list below. (Choose One Answer)

- 1 Red
- 2 Orange
- 3 Yellow
- 4 Green
- 5 Blue
- 6 Indigo
- 7 Violet

(PAGE BREAK)

## T2 TYPE: VI ( LIDL) (LAS 5 1 LE &0

Thanks for completing this screening questionnaire. Your name has been entered into a drawing for \$10,000 in monthly cash awards for participating in this screener. If your name is drawn, your account will be credited the following month. For example, if your name were to be drawn in May, your account would be credited during the first week of June.

You are invited to participate in the survey. It will take about 10 minutes to finish. Your incentive of [Insert Respondent (incentive\_amount)] will be credited to your account within two weeks if you complete the following questionnaire by the date specified in our email.


Your individual answers will be anonymous and strictly confidential, of course. Once you have answered all of the questions on a page, please click on the 'Continue' button.

(PAGE BREAK)

T5 TYPE TO SHA ALIAS ASS IT I ALIAS IT I ALI

Assume that you are in your local drugstore or grocery store to purchase a product for yourself or a member of your family who is not feeling well. One of the products that you see on display catches your eye, so you pick it up to look at it. This product is displayed on the next screen.

(PAGE BREAK)



Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate Right Mouse Click on object and drag for Zoom Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

T8	FYPE F" LT-WBITH LOGIC NETTON FIRE	ALIAS	SIL. 54	nager	3
	LOGIC METPUC TONS SHOW " F IC. "	ा माँ ट			
1	PROURAL MELL MUSER, IN AGE STATES				

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotale Right Mouse Click on object and drag for Zoom Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

```
TO TYPE IL POSICIONS SHOW IN IS ALLIAS. S. 1/3AN 1/2 C
```

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE)(JAVASCRIPT CODE)

```
T11 FUE

1 1/5 A 1 2 1 ...

1 1/5 A 1 2 ...

1
```

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

T12 TYPE BTML/ TextBlock (ALIAS:Amica Image,3" 1 4" LOGIG: INSTRUCTIONS SHOW TO IF IN CENT 26 PROGRAMMER INSERT JO IMAGE ARNIGAS

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

T13 TYPE-PT M TEXT BLOCK ALL AS THE TEXT OF THE TEXT O

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

T14 TYPE IN THE FEX BIGGIN ALLAS, OSC, image !
LOGIC INSTRUCTIONS SHOW IN INCIP.
PROJECTIONS IN AGE IS LILT

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

T15 To ATE TO AT

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)

Please look at the product shown below as you normally would. Take as much time as you need, and be sure to rotate and zoom in to see all sides of the package. Click the "Continue" button when you are finished.

Left Mouse Click on object and drag for Rotate
Right Mouse Click on object and drag for Zoom
Left+Right Mouse Click on object and drag for Pan (JAVASCRIPT CODE) (JAVASCRIPT CODE)


(PAGE BREAK)

Q1A TYPE: Single Respense AUAS: Name of Product
LOGIC INSTRUCTIONS: IF CELL I MUST ANSWER CODE 1 IF CELL: MUST ANSWER CODE
2 AND IF CELL 3 MUST ANSWER CODE 3; OTHERWISE DNOL BUT PAY
RANDOL IZE ANSWERS
DNR CDDE 4

What was the name of the product whose package you looked at? Was it...? (Choose One Answer)

- 1 Similasan
- 2 Amica 30X
- 3 Oscillococcinum
- 4 Don't know/Not sure

(PAGE BREAK)



Did or didn't the package say or imply anything about relief of{{gstrQ1Insert}}, or don't you know? (Choose One Answer)

- 1 Yes, it did
- 2 No, it did not
- 3 Don't know/Not sure


(PAGE BREAK)



We are going to show you three statements about{{gstrT7Inser}}, one at a time. All, some, or none of these statements may be true. Please look at each statement and then indicate if you believe it is true, or you do not believe it is true, or you don't know or are not sure.

Click "Continue" to see the first statement.

(PAGE BREAK)



Decision Analyst

#### ASK QZA1-QZC1 IF INICELL 1, OTHERWISE SKIP TO QZAZ

A government agency like the Food and Drug Administration has approved Similasan as being effective in relieving symptoms associated with the common cold. (Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure

(PAGE BREAK)

## Q2B TYRE: Single Response ALIAS: Manufadure et alimit Similar in LOGIC INSTRUCTIONS:

The manufacturer of Similasan has tested the product on people, to show that it is effective in relieving symptoms associated with the common cold. (Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure


(PAGE BREAK)



The American Medical Association has certified that Similasan is more effective than other cold remedies in relieving symptoms associated with the common cold. (Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure

(PAGE BREAK)



A government agency like the Food and Drug Administration has approved Amica 30X as being effective in relieving aches and pains. (Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure

(PAGE BREAK)



The manufacturer of Arnica 30X has tested the product on people, to show that it is effective in relieving aches and pains.

(Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure

(PAGE BREAK)


## Q2C TYPE SIMPLE RESIGNSE ATTACKED VIENIES ASSOCIATING AND STATES OF THE AND STATES O

The American Medical Association has certified that Amica 30X is more effective than other remedies in relieving aches and pains.

(Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure

(PAGE BREAK)



A government agency like the Food and Drug Administration has approved Oscillococcinum as being effective in relieving symptoms associated with the flu. (Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure

(PAGE BREAK)



The manufacturer of Oscillococcinum has tested the product on people, to show that it is effective in relieving symptoms associated with the flu. (Choose One Answer)

- 1 Yes, I believe that statement is true
- 2 No, I do not believe that statement is true
- 3 Don't know/Not sure

(PAGE BREAK)



The American Medical Association has certified that Oscillococcinum is more effective than other flu remedies in relieving symptoms associated with the flu. (Choose One Answer)

- Yes, I believe that statement is true
- No, I do not believe that statement is true
- Don't know/Not sure

(PAGE BREAK)

ALIAS: D I package say. TYPE: Single Response LOGIC INSTRUCTIONS: IF CELL 1 INSERT TEXT "SIMILASAN IF CELL 2 INSERT TEXT "ARNICA 38X" IF CELL 3 INSERT TEXT "OSCILLOCOCCINUM"

Did or dldn't the{{gstrQ3Insert}}package say that{{gstrQ3Insert}}is a homeopathic product, or don't you know? (Choose One Answer)

- Yes, it did
- No, it did not
- Don't know/Not sure

(PAGE BREAK)

## ABIAS ACOPICAMPIEN , TEX

Thanks for completing this survey. Your account will be credited [Insert Respondent (incentive\_amount)] within the next two weeks.

To view your account balance, please go to the Account Log In page at www.acop.com. Your answers and personal Information are private, protected, and secure (Privacy Policy: http://www.acop.com/PrivacyPolicy.aspx?L=1&PID).

Thanks again for your help!

[Insert Sample Details (contact\_name)]

[Insert Sample Details (contact\_title)]

[Insert Sample Details (panel\_name)]

P.S. Please update your address and personal information if anything has changed since you joined [Insert Sample Details (panel\_name)]. Just go to our update page at [Insert Sample Details (website)].

(TABLE: not parsed)

(PAGE BREAK)

#### SPECIAL FOR THE TANK OF THE PERSON OF THE PE LOGIC INSTRUCTIONS

Thanks for completing this screening questionnaire.

Your name has been entered into a drawing for \$10,000 in monthly cash awards for participating in this screener. If your name is drawn, your account will be credited the following month.

If you are selected to participate in the survey, we will notify you by email within one week.

Your answers and personal information are private, protected, and secure. (Privacy Policy: http://www.acop.com/PrivacyPolicy.aspx?L=1&PID)

If you have any questions about how the screening process works, please click here to view our FAQ page: http://www.acop.com/FAQ.aspx?L=1&PID=#screening

Thanks for your help!

[Insert Sample Details (contact\_name)] [Insert Sample Details (contact\_title)] [Insert Sample Details (panel\_name)]

P.S. Please update your address and personal information if anything has changed since you joined [Insert Sample Details (panel\_name)]. Just go to our update page at [Insert Sample Details (website)].

(TABLE: not parsed)

(PAGE BREAK)